Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Precision Biosciences Inc (NQ: DTIL )

10.48 +0.07 (+0.67%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 35,524
Open 10.60
Bid (Size) 10.10 (1)
Ask (Size) 10.96 (3)
Prev. Close 10.41
Today's Range 10.13 - 10.72
52wk Range 0.2750 - 19.43
Shares Outstanding 113,793,338
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Precision BioSciences Announces Late-Breaking Poster Presentation at the European Association for Study of the Liver (EASL) Congress 2024
From Precision BioSciences, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga

Performance

YTD
+2732.43%
+2732.43%
1 Month
-31.82%
-31.82%
3 Month
+2657.89%
+2657.89%
6 Month
+3304.81%
+3304.81%
1 Year
+1129.33%
+1129.33%

More News

Read More
Precision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics
From Precision BioSciences, Inc.
Via Business Wire
Earnings Preview: Precision BioSciences
Via Benzinga
DTIL Stock Earnings: Precision BioSciences Misses EPS, Misses Revenue for Q4 2023
Via InvestorPlace
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2023 Results on March 27, 2024
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Presents Preclinical Data Highlighting PBGENE-PMM as a Potential Therapy for Primary Mitochondrial Myopathy
From Precision BioSciences
Via Business Wire
Earnings Scheduled For March 27, 2024
Via Benzinga
Precision BioSciences Announces MHRA Approval for Partner iECURE to Expand Phase 1/2 Clinical Trial of ARCUS Gene Editing Program in OTC Deficiency
From Precision BioSciences, Inc.
Via Business Wire
Why Zscaler Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
SPX, Nasdaq Look To Continue Rally
Via Talk Markets
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Via InvestorPlace
Precision BioSciences Announces $40.0 Million Offering of Common Stock and Warrants
From Precision BioSciences, Inc.
Via Business Wire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Precision BioSciences Announces Proposed Public Offering of Common Stock and Warrants
From Precision BioSciences, Inc.
Via Business Wire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Precision BioSciences Announces Non-Exclusive Patent License Agreement with Caribou Biosciences
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Receives Pre-IND Feedback from US FDA for PBGENE-HBV as it Advances Towards Clinical Readiness
From Precision BioSciences
Via Business Wire
Precision BioSciences Promotes Naresh Tanna to Vice President of Investor Relations
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Receives Initial $7.5 Million Cash Payment and Equity Investment from TG Therapeutics for Azel-Cel in Treatment of Autoimmune Diseases
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences to Effect a Reverse Stock Split
From Precision BioSciences, Inc.
Via Business Wire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.